ArticleHead & neck2025
Sarcopenia Trajectories Predict Survival in Operable Head and Neck Cancer.
Article in Head & neck, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Sarcopenia and Survival in Patients With Head and Neck Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis of Prognostic Association.Cancer reports (Hoboken, N.J.) · 2026Pooled it
- Article
- Automated Pretreatment Thoracic CT-Based Body Composition Analysis Predicts Progression-Free Survival in Head and Neck Cancer.Journal of clinical medicine · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundSarcopenia is associated with increased treatment toxicity and survival in head and neck squamous cell cancer (HNSCC). This study evaluates sarcopenia trajectories and their association with overall survival (OS) and disease-free survival (DFS) in operable HNSCC.
methodsPre- and post-treatment body composition metrics of patients with stage II-IV HPV-negative HNSCC undergoing surgery were performed. Sarcopenia trajectories were categorized as remains sarcopenic, remains non-sarcopenic, recovers from sarcopenia, or progresses to sarcopenia using multiple Cox regression.
resultsOf 332 patients, 108 were sarcopenic at baseline, and 106 remained sarcopenic post-treatment. Patients who remained sarcopenic or progressed to sarcopenia demonstrated significantly worse OS (HR: 2.08, 95% CI: 1.27-3.41 and HR: 3.05, 95% CI: 1.40-6.62) and DFS (HR: 1.79, 95% CI: 1.17-2.72 and HR: 2.12, 95% CI: 1.03-4.36), compared to those who remained non-sarcopenic while adjusting for confounding factors.
conclusionSarcopenia trajectories represent dynamic biomarkers that predict oncologic outcome in patients with operable HNSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.